Syntro Health Appointed to Support Stabl-Im Clinical Program
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Trivarx Limited has announced the engagement of Syntro Health to support the formulation of its Stabl-Im investigational product for clinical trials. This partnership marks a significant milestone in the preparations for the planned clinical feasibility study of Stabl-Im, which aims to evaluate its safety and pharmacokinetics. Syntro Health will provide laboratory formulation activities, leveraging its expertise in pharmaceutical manufacturing to aid in the development of the product. The planned feasibility study is set to begin patient enrollment in the first quarter of the following year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from TrivarX
- Change of Director's Interest Notice - David Trimboli
- Change of Director's Interest Notice - Chris Ntoumenopoulos
- Notification of cessation of securities - TRI
- Appendix 4G
- Corporate Governance Statement
Later from TrivarX
- Letter to Shareholders & Notice of AGM & Proxy Form
- September 2026 Quarterly Activities Report and Appendix 4C
- TrivarX Appoints Emeritus Research for Phase 1 Study
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX